Last month, the European Medicines Agency began looking into reports of suicidal ideation and thoughts of self-harm by users of GLP-1 medicines such as Novo Nordisk’s Ozempic, Wegovy (both semaglutide) and Saxenda (liraglutide), and now other GLP-1 receptor agonists.
While the European investigation is ongoing, analyst group TD Cowen says…
Click here to view original post
